PanOptica snags $45 mln Series B funds

PanOptica said Tuesday that it has closed up to $45 million in Series B funding. Novo Ventures and Third Rock Ventures led the round with participation from SV Life Sciences. Headquartered in Bernardsville, NJ, PanOptica is a biopharmaceutical firm focused on ophthalmology therapies.

Alios BioPharma attracts $41 mln

Alios BioPharma has closed $41 million in Series B financing. Investors included Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures. Based in South San Francisco, Alios BioPharma is a biotech firm focused on respiratory viral diseases.

Thesan Pharmaceuticals Closes $16m Series A

Thesan Pharmaceuticals has closed a $16 million Series A financing, co-led by Novo Ventures and Novartis Venture Funds. The company focuses on the development of novel approaches for the treatment of dermatological disorders.

Tobira Therapeutics Appoints Three Execs

Tobira Therapeutics, a developer of innovative antiretroviral therapies for HIV, has appointed three executives in the finance, clinical and pharmaceutical sciences functions. Caroline Loewy joins the company as executive vice president and chief financial officer, Jeff Enejosa, M.D., as senior director, clinical research, and Mark Menning as director, pharmaceutical sciences. Tobira has financial backing from […]

Alder BioPharma Bags $38M Round

Alder BioPharmaceuticals closed a $38 million Series D round led by a new investor—Novo Ventures—and including existing Alder investors Sevin Rosen Funds, Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures and TPG Biotech. Novo’s Peter Bisgaard will join Alder’s board as part of the deal. Alder BioPharma is based in Washington and is develops products […]

Elevation Pharmaceuticals Closes $30M Series B

Elevation Pharmaceuticals Inc. said Wednesday that it had closed $30 million in Series B financing led by new investor Novo Ventures. The company, which develops aerosol therapy for patients living with chronic obstructive pulmonary disease, was also backed in the round by previous investors including Canaan Partners, TPG Biotech, Care Capital and Mesa Verde Venture Partners. As part of the deal, Novo Ventures’ Heath Lukatch joins the company’s board. Elevation is based in San Diego, Calif.

Delenex Therapeutics Inks $19.3M

Zurich-based Delenex Therapeutics has closed on an additional $13 million euro ($19.3 million) to bring its Series A round to 23.5 million euro ($34.8 million). Novo Ventures led the latest tranche, with participation from SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners. Delenex is a biotech company developing therapeutic antibody fragments for diseases with high unmet need.

F-star Seals $21.7M in Fresh Capital

Vienna-based biopharma company f-star GmbH has raised 15 million euro ($21.7 million) in a new financing round led by SR One, the corporate venture capital arm of GlaxoSmithKline. Existing shareholder Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures and MP Healthcare Venture Management also participated in the round. As a result, SR One Partner Dr Deborah Harland and Dr Axel Polack of TVM Capital will join f-star’s Supervisory Board.

PEHUB Community

Join the 12494 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget